Medicare Issues Final Coverage Determination For Healthcare Company

Renalytix plc, a company listed on NASDAQ under the ticker symbol RNLX and also on the London Stock Exchange as RENX, has announced a pivotal development in the coverage of its KidneyIntelX.dkd testing. On June 13, 2024, Medicare issued a final Local Coverage Determination (LCD) for KidneyIntelX.dkd, a diagnostic tool designed to aid in the management of kidney disease among patients with Type 2 diabetes. This decision is set to take effect for dates of service on or after August 1, 2024. The significance of this determination is profound, given the prevalence of kidney disease among diabetic patients in the United States. $Renalytix (RNLX.US)$